home / stock / tara / tara articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TAR...
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therap...
News, Short Squeeze, Breakout and More Instantly...
ArTara Therapeutics Inc. Company Name:
TARA Stock Symbol:
NASDAQ Market:
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TAR...